Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurence Corash

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Transfusion|May 17, 2011
Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation processJose A Cancelas, Larry J Dumont, Neeta Rugg, et al.
Transfusion|December 25, 2024
Characterizing the antibody response to amustaline/glutathione pathogen-reduced red blood cellsChristopher Karim, Anil Panigrahi, Ronald G Pearl, et al.
Transfusion|July 9, 2022
Evaluation of amotosalen and UVA pathogen-reduced apheresis platelets after 7-day storageJose A Cancelas, Jamie R Genthe, Moritz Stolla, et al.
Blood|November 29, 2002
Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trialDick van Rhenen, Hans Gulliksson, Jean-Pierre Cazenave, et al.
Transfusion|September 28, 2006
A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpuraPaul D Mintz, Anne Neff, Malcolm MacKenzie, et al.
Trials|May 26, 2026
A randomized, double-blind, controlled, parallel group study with amustaline/glutathione pathogen reduced red blood cells in regions at potential risk for Zika virus transfusion-transmitted infections (RedeS Study)-protocol for a phase 3 clinical trialEdgardo F Cartagena Ayala, Lumen Vera Colon, Yesim Aydinok, et al.
Blood|May 13, 2004
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT TrialJeffrey McCullough, David H Vesole, Richard J Benjamin, et al.
Transfusion|September 2, 2022
Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patientsMaja Weisser, Nina Khanna, Anemone Hedstueck, et al.
Trials|December 12, 2023
Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study-protocol for a phase 3, randomized, controlled trialEdward L Snyder, Michael E Sekela, Ian J Welsby, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Transfusion|May 17, 2011
Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation processJose A Cancelas, Larry J Dumont, Neeta Rugg, et al.
Transfusion|December 25, 2024
Characterizing the antibody response to amustaline/glutathione pathogen-reduced red blood cellsChristopher Karim, Anil Panigrahi, Ronald G Pearl, et al.
Transfusion|July 9, 2022
Evaluation of amotosalen and UVA pathogen-reduced apheresis platelets after 7-day storageJose A Cancelas, Jamie R Genthe, Moritz Stolla, et al.
Blood|November 29, 2002
Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trialDick van Rhenen, Hans Gulliksson, Jean-Pierre Cazenave, et al.
Transfusion|September 28, 2006
A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpuraPaul D Mintz, Anne Neff, Malcolm MacKenzie, et al.
Trials|May 26, 2026
A randomized, double-blind, controlled, parallel group study with amustaline/glutathione pathogen reduced red blood cells in regions at potential risk for Zika virus transfusion-transmitted infections (RedeS Study)-protocol for a phase 3 clinical trialEdgardo F Cartagena Ayala, Lumen Vera Colon, Yesim Aydinok, et al.
Blood|May 13, 2004
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT TrialJeffrey McCullough, David H Vesole, Richard J Benjamin, et al.
Transfusion|September 2, 2022
Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patientsMaja Weisser, Nina Khanna, Anemone Hedstueck, et al.
Trials|December 12, 2023
Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study-protocol for a phase 3, randomized, controlled trialEdward L Snyder, Michael E Sekela, Ian J Welsby, et al.
Pageof 7